Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485272 | 0.92 | KDM4E (0.41) | SLC6A2SLC6A4SLC6A3KDM4EDRD2 | |
| SCHEMBL485650 | 0.89 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3KDM4EMAPT | |
| SCHEMBL5202868 | 0.85 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3SMYD3SSTR4 | |
| SCHEMBL485206 | 0.85 | KDM4E (0.40) | SLC6A2SLC6A4SLC6A3KDM4EDRD2 | |
| SCHEMBL485330 | 0.84 | KDM4E (0.39) | SLC6A2SLC6A4SLC6A3KDM4EDRD2 | |
| SCHEMBL485131 | 0.84 | CHRM1 (0.36) | KDM4ECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL485215 | 0.84 | KDM4E (0.39) | SLC6A2SLC6A4SLC6A3KDM4EDRD2 | |
| SCHEMBL485306 | 0.81 | KDM4E (0.40) | SLC6A2SLC6A4SLC6A3KDM4EDRD2 | |
| SCHEMBL485585 | 0.81 | KDM4E (0.40) | SLC6A2SLC6A4SLC6A3KDM4EDRD2 | |
| SCHEMBL485324 | 0.76 | KDM4E (0.42) | KDM4EDRD2DRD3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | SLC6A2 1191/4885SLC6A4 966/4885SLC6A3 1129/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | SLC6A2 1191/4885SLC6A4 966/4885SLC6A3 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.